Effect of one-week treatment with vaginal estrogen preparations on serum estrogen levels in postmenopausal women

Menopause

Volumn 16, Issue 1, 2009, Pages 30-36

  Labrie, Fernand ^a   Cusan, Leonello ^a   Gomez, José Luis ^a   Côté, Isabelle ^a   Bérubé, René ^a   Bélanger, Patrick ^a   Martel, Céline ^a   Labrie, Claude ^a  

^a LAVAL UNIVERSITY   (Canada)

Author keywords

Breast cancer; Estrogens; Premarin cream; Vagifem; Vaginal atrophy

Indexed keywords

CONJUGATED ESTROGEN; ESTRADIOL; ESTROGEN; ESTRONE;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BREAST TENDERNESS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREAM; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG TOLERABILITY; ESTRADIOL BLOOD LEVEL; ESTROGEN BLOOD LEVEL; ESTRONE BLOOD LEVEL; FEMALE; HUMAN; MASS SPECTROMETRY; MENOPAUSAL SYNDROME; POSTMENOPAUSE; RANDOMIZED CONTROLLED TRIAL; TABLET; TREATMENT DURATION; VAGINA BLEEDING; BLOOD; INTRAVAGINAL DRUG ADMINISTRATION; MASS FRAGMENTOGRAPHY; MIDDLE AGED; PROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY;

ADMINISTRATION, INTRAVAGINAL; ADULT; AGED; ESTRADIOL; ESTROGENS; ESTROGENS, CONJUGATED (USP); ESTRONE; FEMALE; GAS CHROMATOGRAPHY-MASS SPECTROMETRY; HUMANS; MIDDLE AGED; POSTMENOPAUSE; PROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY;

EID: 64049083020     PISSN: 10723714     EISSN: None     Source Type: Journal    
DOI: 10.1097/gme.0b013e31817b6132     Document Type: Article

References (53)

1. Rossin-Amar B. Vaginal dryness in the menopausal woman (physiological and psychological aspects). Gynecol Obstet Fertil 2000;28:245-249.
2. Pandit L, Ouslander JG. Postmenopausal vaginal atrophy and atrophic vaginitis. Am J Med Sci 1997;314:228-231.
3. Notelovitz M. Urogenital atrophy and low-dose vaginal estrogen therapy. Menopause 2000;7:140-142.
4. Frank E, Anderson C, Rubinstein D. Frequency of sexual dysfunction in "normal" couples. N Engl J Med 1978;299:111-115.
5. Semmens JP, Wagner G. Estrogen deprivation and vaginal function in postmenopausal women. JAMA 1982;248:445-448.
6. Leiblum S, Bachmann G, Kemmann E, Colburn D, Swartzman L. Vaginal atrophy in the postmenopausal women. The importance of sexual activity and hormones. JAMA 1983;249:2195-2198.
7. McCoy NK, Davidson JM. A longitudinal study of the effects of menopause on sexuality. Maturitas 1985;7:203-210.
8. Dennerstein L, Dudley EC, Hopper JL, Burger H. Sexuality, hormones and the menopausal transition. Maturitas 1997;26:83-93.
9. Dennerstein L, Dudley E, Burger H. Are changes in sexual functioning during midlife due to aging or menopause? Fertil Steril 2001;76:456-460.
10. Berman JR, Berman LA, Werbin TJ, Goldstein I. Female sexual dysfunction: anatomy, physiology, evaluation and treatment options. Curr Opin Urol 1999;9:563-568.
11. Mattson LA, Culberg G, Eriksson O, Kruitsson F. Vaginal administration of low dose estradiol - effects on endometrium and vaginal cytology. Maturitas 1989;11:217-222.
12. Gallagher JC, Riggs BL. Current concepts in nutrition. Nutrition and bone disease. N Engl J Med 1978;298:193-195.
13. Martin PL, Yen SS, Burnier AM, Hermann H. Systemic absorption and sustained effects of vaginal estrogen creams. JAMA 1979;242:2699-2700.
14. Furuhjelm M, Karlgren E, Carlstrom K. Intravaginal administration of conjugated estrogens in premenopausal and postmenopausal women. Int J Gynaecol Obstet 1980;17:335-339.
15. Deutsch S, Ossowski R, Benjamin I. Comparison between degree of systemic absorption of vaginally and orally administered estrogens at different dose levels in postmenopausal women. Am J Obstet Gynecol 1981;139:967-968.
16. Mandel FP, Geola FL, Meldrum DR, et al. Biological effects of various doses of vaginally administered conjugated equine estrogens in postmenopausal women. J Clin Endocrinol Metab 1983;57:133-139.
17. Beral V. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 2003;362:419-427.
18. Rosenberg LU, Magnusson C, Lindstrom E, Wedren S, Hall P, Dickman PW. Menopausal hormone therapy and other breast cancer risk factors in relation to the risk of different histological subtypes of breast cancer: a case-control study. Breast Cancer Res 2006;8:R11.
19. Nachtigall LE. Clinical trial of the estradiol vaginal ring in the U.S. Maturitas 1995;22 (Suppl):S43-S47.
20. Kvorning JDN, Jensen HK. Pharmaceutical development of low-dose estradiol vagitories. Paper presented at: International Workshop, 1986, Copenhagen.
21. Kendall A, Dowsett M, Folkerd E, Smith I. Caution: Vaginal estradiol appears to be contraindicated in postmenopausal women on adjuvant aromatase inhibitors. Ann Oncol 2006;17:584-587.
22. Notelovitz M, Funk S, Nanavati N, Mazzeo M. Estradiol absorption from vaginal tablets in postmenopausal women. Obstet Gynecol 2002;99:556-562.
23. Schiff I, Tulchinsky D, Ryan KJ. Vaginal absorption of estrone and 17β-estradiol. Fertil Steril 1977;28:1063-1066.
24. Rioux JE, Devlin C, Gelfand MM, Steinberg WM, Hepburn DS. 17β-Estradiol vaginal tablet versus conjugated equine estrogen vaginal cream to relieve menopausal atrophic vaginitis. Menopause 2000;7:156-161.
25. Dew JE, Wren BG, Eden JA. A cohort study of topical vaginal estrogen therapy in women previously treated for breast cancer. Climacteric 2003;6:45-52.
26. Weisberg E, Ayton R, Darling G, et al. Endometrial and vaginal effects of low-dose estradiol delivered by vaginal ring or vaginal tablet. Climacteric 2005;8:83-92.
27. Long CY, Liu CM, Hsu SC, Wu CH, Wang CL, Tsai EM. A randomized comparative study of the effects of oral and topical estrogen therapy on the vaginal vascularization and sexual function in hysterectomized postmenopausal women. Menopause 2006;13:737-743.
28. Johansson C, Gunnarsson P. Pharmokinetics of Estradiol After Application of an Estradiol Releasing Vaginal Ring. Uppsala, Sweden: Kabi Pharmacia AB, 1992.
29. Gupta P, Ozel B, Stanczyk FZ, Felix JC, Mishell DR Jr. The effect of transdermal and vaginal estrogen therapy on markers of postmenopausal estrogen status. Menopause 2008;15:94-97.
30. Rigg LA, Hermann H, Yen SS. Absorption of estrogens from vaginal creams. N Engl J Med 1978;298:195-197.
31. Salminen HS, Saaf ME, Johansson SE, Ringertz H, Strender LE. The effect of transvaginal estradiol on bone in aged women: a randomised controlled trial. Maturitas 2007;57:370-381.
32. Rinaldi S, Dechaud H, Biessy C, et al. Reliability and validity of commercially available, direct radioimmunoassays for measurement of blood androgens and estrogens in postmenopausal women. Cancer Epidemiol Biomarkers Prev 2001;10:757-765.
33. Labrie F, Belanger A, Belanger P, et al. Metabolism of DHEA in postmenopausal women following percutaneous administration. J Steroid Biochem Mol Biol 2007;103:178-188.
34. Bouchard C. Herbal alternatives as substitutes for hormone therapy in urogenital atrophy: scientific evidence is needed. Menopause 2008;15:12-13.
35. Lyytinen H, Pukkala E, Ylikorkala O. Breast cancer risk in postmenopausal women using estrogen-only therapy. Obstet Gynecol 2006;108:1354-1360.
36. Steinberg KK, Thacker SB, Smith SJ, et al. A meta-analysis of the effect of estrogen replacement therapy on the risk of breast cancer. JAMA 1991;265:1985-1990.
37. Sillero-Arenas M, Delgado-Rodriguez M, Rodigues-Canteras R, Bueno-Cavanillas A, Galvez-Vargas R. Menopausal hormone replacement therapy and breast cancer: a meta-analysis. Obstet Gynecol 1992;79:286-294.
38. Colditz GA, Egn KM, Stampfer MJ. Hormone replacement therapy and risk of breast cancer: results from epidemiologic studies. Am J Obstet Gynecol 1993;168:1473-1480.
39. Colditz GA, Hankinson SE, Hunter DJ, et al. The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. N Engl J Med 1995;332:1589-1593.
40. Corrao G, Zambon A, Conti V, et al. Menopause hormone replacement therapy and cancer risk: an Italian record linkage investigation. Ann Oncol 2008;19:150-155.
41. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-333.
42. Garg PP, Kerlikowske K, Subak L, Grady D. Hormone replacement therapy and the risk of epithelial ovarian carcinoma: a meta-analysis. Obstet Gynecol 1998;92:472-479.
43. Coughlin SS, Giustozzi A, Smith SJ, Lee NC. A meta-analysis of estrogen replacement therapy and risk of epithelial ovarian cancer. J Clin Epidemiol 2000;53:367-375.
44. Rodriguez C, Patel AV, Calle EE, Jacob EJ, Thun MJ. Estrogen replacement therapy and ovarian cancer mortality in a large prospective study of US women. JAMA 2002;285:1460-1465.
45. Riman T, Dickman PW, Nilsson S, et al. Hormone replacement therapy and the risk of invasive epithelial ovarian cancer in Swedish women. J Natl Cancer Inst 2002;94:497-504.
46. Lacey JV, Mink PJ, Lubin JH, et al. Menopausal hormone replacement therapy and risk of ovarian cancer. JAMA 2002;288:334-341.
47. Grady D, Gebretsadik T, Kerlikowske K, Ernster V, Petitti D. Hormone replacement therapy and endometrial cancer risk: a meta-analysis. Obstet Gynecol 1995;85:304-313.
48. Gambrell RD Jr, Massey FM, Castaneda TA, Ugenas AJ, Ricci CA, Wright JM. Use of the progestogen challenge test to reduce the risk of endometrial cancer. Obstet Gynecol 1980;55:732-738.
49. Persson I, Adami HO, Bergkvist L, et al. Risk of endometrial cancer after treatment with oestrogens alone or in conjunction with progestogens: results of a prospective study. BMJ 1989;298:147-151.
50. Voigt LF, Weiss NS, Chu J, Daling JR, McKnight B, van Belle G. Progestagen supplementation of exogenous oestrogens and risk of endometrial cancer. Lancet 1991;338:274-277.
51. Jick SS, Walker AM, Jick H. Estrogens, progesterone, and endometrial cancer. Epidemiology 1993;4:20-24.
52. Fallowfield L, Cella D, Cuzick J, Francis S, Locker G, Howell A. Quality of life of postmenopausal women in the Arimidex, Tamoxifen, Alone or in Combination (ATAC) Adjuvant Breast Cancer Trial. J Clin Oncol 2004;22:4261-4271.
53. Morales L, Neven P, Timmerman D, et al. Acute effects of tamoxifen and third-generation aromatase inhibitors on menopausal symptoms of breast cancer patients. Anticancer Drugs 2004;15:753-760.